December 5, 2011
The Department of Health and Human Services (HHS) Panel on Pediatric Antiretroviral Therapy and Management Guidelines (the Pediatric Guidelines Panel) is accepting nominations for new members with clinical research and/or practice expertise in management of HIV infection in children. The Panel anticipates one vacancy for a 3-year term beginning January 2012, with potential for reappointment for a second term.
The Pediatric Guidelines Panel is a working group of the Office of AIDS Research Advisory Council (OARAC) of the National Institutes of Health (NIH). The Panel is composed of approximately 25 members who are clinicians, researchers, academicians, and HHS representatives with expertise in pediatric HIV management, and community representatives with knowledge of HIV infection in children. The Panel meets monthly via teleconferencing and on occasion in person to review and critically evaluate emerging scientific data relating to antiretroviral therapy in infants and children. The members actively engage in the preparation and update of the "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection." The document is widely used by HIV practitioners and researchers in the United States. (To view the latest version of the guidelines visit the AIDSinfo clinical guidelines portal.)
Panel members are not compensated for their time commitment and travel support is not provided for participation.
Please include with nomination the candidate's curriculum vitae and a letter of nomination or letter of interest outlining what qualities and contributions the candidate may bring to the Panel. The deadline for nominations is December 30, 2011. Please e-mail nominations to Lynne M. Mofenson, M.D., Panel Executive Secretary, at LM65D@nih.gov or Lynne.Mofenson@nih.hhs.gov. or send to the following address: Lynne M. Mofenson, M.D., National Institute of Child Health and Human Development, National Institutes of Health, 6100 Executive Boulevard, Room 4B11, Rockville, MD 20852 (Fax: 301-496-8678).
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.